Canaccord analyst George Gianarikas initiated coverage of ASP Isotopes with a Buy rating and $4.50 price target “Hidden in the depths of South Africa’s sophisticated yet discreet nuclear technology industry, ASP holds significant promise,” the analyst tells investors in a research note. The firm says the company could help the West counter Russia’s dominance of the uranium supply chain. In addition, ASP’s enrichment technology could yield several isotopes that may well advance the market for nuclear medicine and accelerate the adoption of advanced semiconductor technologies, contends Canaccord.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASPI:
- ASP Isotopes completes construction phase of Ytterbium-176 enrichment facility
- ASP Isotopes price target lowered to $4.50 from $5.50 at H.C. Wainwright